A Study of LY2510924 and Sunitinib in Patients With Metastatic Renal Cell Carcinoma

NCT01391130 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

110

Enrollment

INDUSTRY

Sponsor class

Stopped Study Terminated due to Insufficient Efficacy

Conditions

Metastatic Clear Cell Renal Cell Carcinoma

Interventions

DRUG: LY2510924
DRUG: Sunitinib

Sponsor

Eli Lilly and Company